NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age

CompletedPhase 3

Sponsor: Pfizer

Conditions: Meningococcal Vaccine

Interventions: MenABCWY, Saline, Trumenba, MenACWY-CRM

Countries: United States, Czechia, Denmark, Hungary, Poland

The aim of this study is to determine the immunologic noninferiority of MenABCWY to licensed vaccines Trumenba and MenACWY-CRM (Menveo) by assessing the safety and immunogenicity of MenABCWY and the comparators in both ACWY-naïve and ACWY-experienced healthy participants ≥10 to \<26 years of age.

Eligibility overview

Sex: ALL

Age: 10 Years to 25 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Male or female subject aged \>=10 and \<26 years at the time of randomization.
* Healthy subject as determined by medical history, physical examination, and judgment of the investigator.
* Negative urine pregnancy test for all female subjects.
* ACWY-naïve participants: Participants who have never received a prior dose of a meningococcal vaccine containing ACWY serogroups.
* ACWY-experienced participants: Participants who have received not more than 1 prior dose, no sooner than 4 years prior to the date of randomization of Menactra or Menveo.

Exclusion Criteria:

* Previous vaccination with any meningococcal group B vaccine, any purely polysaccharide (nonconjugate) meningococcal vaccine, or monovalent/bivalent meningococcal vaccine.- Subjects receiving any allergen immunotherapy with a non-licensed product or receiving allergen immunotherapy with a licensed product and are not on stable maintenance doses.
* A known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired defects in B cell function, those receiving chronic systemic (oral, intravenous, or intramuscular) corticosteroid therapy, or those receiving immunosuppressive therapy. Subjects in the United States with terminal complement deficiency are excluded from participation in this study.
* Significant neurological disorder or history of seizure (excluding simple febrile seizure).
* Current chronic use of systemic antibiotics.
* Participation in other studies involving investigational drug(s) or investigational vaccine(s) within 28 days prior to study entry and/or during study participation.
* Any neuroinflammatory or autoimmune condition, including, but not limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
* History of microbiologically proven disease caused by N meningitidis or Neisseria gonorrhoeae.
* Receipt of any blood products, including immunoglobulin, within 6 months before the first study vaccination.

Locations (78)

Birmingham, Alabama, United States
Birmingham, Alabama, United States
Tempe, Arizona, United States
Banning, California, United States
Madera, California, United States
Paramount, California, United States
Paramount, California, United States
Colorado Springs, Colorado, United States
Cooper City, Florida, United States
Coral Gables, Florida, United States
Jupiter, Florida, United States
Lake Worth, Florida, United States
Miami, Florida, United States
Miami, Florida, United States
Miami, Florida, United States
Miami Lakes, Florida, United States
Miami Lakes, Florida, United States
Ormond Beach, Florida, United States
Oviedo, Florida, United States
Tampa, Florida, United States
Chamblee, Georgia, United States
Meridian, Idaho, United States
Nampa, Idaho, United States
Mishawaka, Indiana, United States
South Bend, Indiana, United States
Ankeny, Iowa, United States
West Des Moines, Iowa, United States
El Dorado, Kansas, United States
Newton, Kansas, United States
Lexington, Kentucky, United States
+ 48 more on CT.gov